Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Non-Current Assets (2016 - 2025)

Spero Therapeutics' Non-Current Assets history spans 10 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 50.02% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $9.2 million, down 85.18%, while the annual FY2025 figure was $1.6 million, 50.02% down from the prior year.
  • Non-Current Assets reached $1.6 million in Q4 2025 per SPRO's latest filing, down from $1.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $51.2 million in Q4 2023 to a low of $1.6 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $12.5 million, with a median of $11.4 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: skyrocketed 355.68% in 2023, then crashed 93.62% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $13.2 million in 2021, then decreased by 14.91% to $11.2 million in 2022, then skyrocketed by 355.68% to $51.2 million in 2023, then plummeted by 93.62% to $3.3 million in 2024, then tumbled by 50.02% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Non-Current Assets are $1.6 million (Q4 2025), $1.8 million (Q3 2025), and $2.7 million (Q2 2025).